[ad_1]
– IONIS-FB-LRx achieved a 44% mean reduction in proteinuria in patients treated for 6 months
– Roche to advance IONIS-FB-LRx into Phase 3 development in H1 2023
CARLSBAD, Calif., Nov. 7, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). Results from the study were presented in a poster session at the American Society of Nephrology’s (ASN) Kidney Week 2022.
In the Phase 2 study, IONIS-FB-LRx met its primary endpoint of change in 24-hour urinary protein, demonstrating a 44% mean reduction in proteinuria from baseline to week 29. Kidney function, as measured by estimated glomerular filtration rate (eGFR), was maintained in all patients in the study. IONIS-FB-LRx achieved robust and sustained reductions in plasma complement Factor B (CFB), Alternative Pathway Activity (AH50), and urinary complement fragment Ba (Factor Ba). IONIS-FB-LRx also demonstrated a favorable safety and tolerability profile in this study.
“We are extremely pleased with the results from this proof-of-concept Phase 2 study of IONIS-FB-LRxwhich demonstrated the potential to treat IgAN by inhibiting complement Factor B,” said Richard GearyPh.D., executive vice president, drug …
Full story available on Benzinga.com
[ad_2]
Source link
